FR16C0004I1 - CEPHEM COMPOUNDS - Google Patents

CEPHEM COMPOUNDS

Info

Publication number
FR16C0004I1
FR16C0004I1 FR16C0004C FR16C0004I1 FR 16C0004 I1 FR16C0004 I1 FR 16C0004I1 FR 16C0004 C FR16C0004 C FR 16C0004C FR 16C0004 I1 FR16C0004 I1 FR 16C0004I1
Authority
FR
France
Prior art keywords
cephem compounds
cephem
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR16C0004I1 publication Critical patent/FR16C0004I1/en
Application granted granted Critical
Publication of FR16C0004I2 publication Critical patent/FR16C0004I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR16C0004C 2002-10-30 2016-02-03 CEPHEM COMPOUNDS Active FR16C0004I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (en) 2002-10-30 2003-10-27 Cephem compounds

Publications (2)

Publication Number Publication Date
FR16C0004I1 true FR16C0004I1 (en) 2016-03-25
FR16C0004I2 FR16C0004I2 (en) 2017-01-06

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0004C Active FR16C0004I2 (en) 2002-10-30 2016-02-03 CEPHEM COMPOUNDS

Country Status (20)

Country Link
US (2) US7129232B2 (en)
EP (1) EP1556389B9 (en)
JP (1) JP4448821B2 (en)
KR (1) KR101023035B1 (en)
AR (1) AR041729A1 (en)
AT (1) ATE368042T1 (en)
BE (1) BE2016C002I2 (en)
BR (1) BRPI0315188B8 (en)
CA (1) CA2504730C (en)
DE (1) DE60315178T3 (en)
DK (1) DK1556389T6 (en)
ES (1) ES2290498T7 (en)
FR (1) FR16C0004I2 (en)
HK (1) HK1086566A1 (en)
HU (1) HUS1600008I1 (en)
LU (1) LU92943I2 (en)
NL (1) NL300793I1 (en)
PT (1) PT1556389E (en)
TW (1) TWI319403B (en)
WO (1) WO2004039814A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010002A (en) * 2001-05-01 2004-06-30 Fujisawa Pharmaceutical Co Cephem compounds.
ATE368042T1 (en) * 2002-10-30 2007-08-15 Astellas Pharma Inc CEPHEMEM COMPOUNDS
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
WO2005027909A1 (en) * 2003-09-18 2005-03-31 Astellas Pharma Inc. Cephem compounds
JP4792974B2 (en) * 2003-12-25 2011-10-12 小野薬品工業株式会社 Azetidine ring compound and pharmaceuticals thereof
WO2007119511A1 (en) * 2006-03-16 2007-10-25 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
ITFE20060029A1 (en) * 2006-10-17 2008-04-18 Gruppo Kemon Spa PRIMARY HETEROCYCLIC INTERMEDIATES FOR THE OXIDATIVE COLORING OF PYRACTIONAL HAIR
CA2935651A1 (en) 2007-10-09 2009-04-16 Gladius Pharmaceuticals Corporation Broad spectrum beta-lactamase inhibitors
CN105130967B (en) * 2011-05-13 2018-04-17 阵列生物制药公司 Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors
EA028342B1 (en) 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Methods for treating pneumonia
EP2628730B1 (en) * 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
CA2886402A1 (en) 2012-09-27 2014-04-03 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140274999A1 (en) 2013-03-14 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
NZ700372A (en) * 2013-03-15 2016-01-29 Merck Sharp & Dohme Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CR20160583A (en) 2014-05-15 2017-02-23 Array Biopharma Inc 1 - ((3S, 4R) -4- (3-FLUOROPHENYL) -1- (2-METOXYETHYL) PIRROLIDIN-3-IL) -3- (4-METHYL-3- (2-METHYLPIRIMIDIN-5-IL) - 1-FENIL-1H-PIRAZOL-5-IL) UREA AS INHIBITOR OF TRKA CINASA
CN110204558B (en) 2014-08-15 2022-05-06 默沙东公司 Synthesis of cephalosporin compounds
US10221196B2 (en) 2014-08-15 2019-03-05 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
US10000510B2 (en) 2014-08-18 2018-06-19 Merck Sharp & Dohme Corp. Salt forms of ceftolozane
WO2016095860A1 (en) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
US10059680B2 (en) 2014-12-18 2018-08-28 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
US10214543B2 (en) 2014-12-30 2019-02-26 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
EP3313821B1 (en) * 2015-06-29 2019-04-10 Sandoz AG Process for the preparation of carbamoylamino pyrazole derivatives
WO2017042188A1 (en) 2015-09-08 2017-03-16 Sandoz Ag Process for preparing ceftolozane from 7-aminocephalosporanic acid (7-aca)
KR20180066264A (en) 2015-12-10 2018-06-18 나에자-알지엠 파마슈티칼스 유엘씨 Cephem compounds, their preparation and uses
EP3468968B1 (en) 2016-06-06 2024-01-10 Merck Sharp & Dohme LLC Solid forms of ceftolozane and processes for preparing
CN107586305A (en) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 A kind of beta-lactam class compound carboxyl and hydroxyl protecting group removal methods
WO2019145784A2 (en) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Combination therapies for multi-drug resistant pathogens
CN109369535A (en) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 A kind of preparation method of carbamoylamino pyrazole derivative compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (en) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (en) * 1990-02-27 1991-09-30 후지사와 토모키치로 Cefem compound
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (en) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk Cephem compound, its production and antibacterial agent containing the compound
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
MXPA03010002A (en) * 2001-05-01 2004-06-30 Fujisawa Pharmaceutical Co Cephem compounds.
ATE368042T1 (en) * 2002-10-30 2007-08-15 Astellas Pharma Inc CEPHEMEM COMPOUNDS
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
WO2005027909A1 (en) * 2003-09-18 2005-03-31 Astellas Pharma Inc. Cephem compounds

Also Published As

Publication number Publication date
BE2016C002I2 (en) 2023-03-07
NL300793I2 (en) 2016-03-15
HK1086566A1 (en) 2006-09-22
WO2004039814A1 (en) 2004-05-13
CA2504730A1 (en) 2004-05-13
TW200410977A (en) 2004-07-01
EP1556389B9 (en) 2015-09-09
JP2006506459A (en) 2006-02-23
DE60315178T2 (en) 2008-04-30
US7129232B2 (en) 2006-10-31
NL300793I1 (en) 2016-03-15
DK1556389T3 (en) 2007-11-26
BRPI0315188B8 (en) 2021-05-25
HUS1600008I1 (en) 2016-03-29
TWI319403B (en) 2010-01-11
DE60315178T3 (en) 2015-06-18
DK1556389T6 (en) 2015-05-11
DE60315178D1 (en) 2007-09-06
ES2290498T7 (en) 2015-07-10
EP1556389A1 (en) 2005-07-27
LU92943I2 (en) 2016-03-14
US20040132994A1 (en) 2004-07-08
CA2504730C (en) 2011-04-12
KR20050084897A (en) 2005-08-29
EP1556389B3 (en) 2015-04-01
JP4448821B2 (en) 2010-04-14
ATE368042T1 (en) 2007-08-15
ES2290498T3 (en) 2008-02-16
AR041729A1 (en) 2005-05-26
PT1556389E (en) 2007-11-08
BRPI0315188B1 (en) 2017-04-25
FR16C0004I2 (en) 2017-01-06
KR101023035B1 (en) 2011-03-24
EP1556389B1 (en) 2007-07-25
BR0315188A (en) 2005-09-06
US20070037786A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
FR16C0004I2 (en) CEPHEM COMPOUNDS
MA27105A1 (en) NEW COMPOUNDS
NO20043647L (en) Bronnsystem
DE60312848D1 (en) CONNECTION CONNECTION
ATE318817T1 (en) AZA-ARYLPIPERAZINE
NO20044046L (en) Substituted hydroxyethylamines
DE50301200D1 (en) WISCHBLATT
NO20033280D0 (en) Avisningsopplösning
IS7381A (en) compounds
DE60326590D1 (en) TEND LAMOTRIGIN
ATE463248T1 (en) CEPHEM COMPOUNDS
IS7414A (en) Oxo-azabicyclic compounds
NO20040429L (en) Stromningsrorisolasjonssystem
NO20045659L (en) compounds
NO20031114D0 (en) Signal
ATE318269T1 (en) CEPHEM COMPOUNDS
DE60331717D1 (en) Zündunterbrecherschaltkreis
ATE496887T1 (en) SUBSTITUTED 5-AMINOMETHYL-1H-PYRROL-2-CARBONS UREAMIDE
DE60336678D1 (en) EITAKTSP LMOTORS
DE50303317D1 (en) SLOT-BREAKER
FR2839740B3 (en) IMPROVED BOURRELET
ATE350379T1 (en) SUBSTITUTED BENZDIOXEPINES
DE60305506D1 (en) cephalosporins
AT5889U3 (en) BRENNHOLZSPLEISSER
AU2003274754A8 (en) Cephem compounds